Cat No.
CEI-0243
Description
Rivaroxaban (Xarelto, BAY 59-7939)can inhibit Factor Xa with IC50 of 0.7 nM.
CAS No.
366789-02-8
Targets
Factor Xa
Chemical Name
(S)-5-chloro-N-((2-oxo-3-(4-(3-oxomorpholino)phenyl)oxazolidin-5-yl)methyl)thiophene-2-carboxamide
M.Wt
435.88
Purity
>99%
Solubility
DSMO 87 mg/mL Water
Storage
2 years at -20 centigrade
In vitro
Rivaroxaban is an oral, direct inhibitor of Factor Xa (FXa), being developed for the prevention and treatment of arterial and venous thrombosis with a Ki of 0.4 nM. Rivaroxaban exhibits high permeability and polarized transport across Caco-2 cells as a substrate of the P-gp, but exhibits no inhibitory effect on P-gp-mediated drug transport up to concentrations of 100 uM in vitro.
In vivo
Rivaroxaban reduces venous thrombosis in a dose dependent manner (ED50 0.1 mg/kg i.v.) in a rat venous stasis model. Rivaroxaban reduces arterial thrombus formation in an arteriovenous (AV) shunt in rats (ED50 5.0 mg/kg p.o.) and rabbits (ED50 0.6 mg/kg p.o.).
